Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

Infographic showing that more than half of every dollar spent on brand name medicines goes to PBMs

New study: Entities that don’t make medicines get half of what is spent on those medicines

Elizabeth Carpenter
Half of every dollar spent on brand medicines goes to entities that play no role in the research, development, or manufacturing of those medicines, according to a new analysis by Berkeley Research Group (BRG).
Woman looking at bottle of medicine in pharmacy

FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs

Molly Jenkins Headshot
Molly Jenkins
The three largest Pharmacy Benefit Managers (PBMs) continue to abuse the health care system, significantly marking up a wide range of lifesaving medicines according to a new report from the Federal Trade Commission (FTC).

NYT exposes hospitals, middlemen make millions off a hospital markup program

Drew Voytal
A ground-breaking New York Times investigation reveals how a for-profit federal contractor helps hospitals abuse the 340B program to charge huge markups on medicines.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.